Hurone AI adds former CMS chief medical officer Lee Fleisher to board

Hurone AI has appointed Lee A. Fleisher, the former chief medical officer at CMS, to its Advisory Board as the company expands its cancer-navigation platform across major U.S. academic medical institutions. The move gives Hurone AI deeper policy and reimbursement expertise as it pushes to scale AI tools for cancer care in underserved areas. Why it matters: - Hurone AI is trying to scale a cancer-navigation platform that health systems can trust, deploy and sustain. - Dr. Fleisher’s experience at CMS adds policy, regulatory and reimbursement expertise at a moment when Hurone AI is building for national growth. - The appointment could help Hurone AI navigate federal standards and coverage pathways as it expands into areas with limited specialist access. What happened: - Hurone AI announced the appointment of Lee A. Fleisher, MD, ML, to its Advisory Board on June 17, 2026. - Fleisher is the former Chief Medical Officer and Director of the Center for Clinical Standards and Quality at CMS, a role he held from 2020 to 2023. - Hurone AI said Fleisher will help the company bridge innovative AI technology with federal health policy standards. The details: - At CMS, Fleisher oversaw national clinical standards and Medicare coverage determinations for the U.S. healthcare system. - Fleisher is co-founder and CEO of Rubrum Advising. - He also serves as a member of the National Academy of Medicine. - Fleisher is a senior advisor and visiting fellow at the Duke Margolis Institute for Health Policy, the Bipartisan Policy Center and Milken Institute FasterCures. - Before CMS, Fleisher was Chair of Anesthesiology and Critical Care at the University of Pennsylvania. - Fleisher remains Professor Emeritus and a practicing anesthesiologist at Penn. - Hurone AI said its platform is expanding across major U.S. academic medical institutions. - The company said its mission is to help ensure every person with cancer receives the same standard of care as patients at leading cancer centers, regardless of location or circumstances. - Hurone AI said Fleisher’s understanding of federal reimbursement pathways and quality standards will support expansion into regions where specialized medical expertise is scarce. - Hurone AI described its platform as an AI-native navigation infrastructure for oncology that extends clinicians beyond the clinic. - The company said the platform is built on proprietary clinical data and is natively integrated into the Epic EHR. - Hurone AI said its system automates complex workflows and social risk stratification to improve adherence and outcomes while reducing administrative burden. - The company said deployments at top-tier research hospitals provide scalable data architecture to address health disparities. - Hurone AI included a website for more information: More information . Between the lines: - Fleisher’s background suggests Hurone AI is prioritizing credibility with regulators, payers and health systems, not just product development. - The company’s focus on rural and underserved patients points to a strategy aimed at proving value where access gaps are most visible. - The board appointment also signals that AI in oncology is moving from a technology story to a policy and reimbursement story. What’s next: - Hurone AI is expected to keep building the clinical and regulatory foundation needed for broader national deployment. - Fleisher’s involvement could help shape how the company positions its platform for coverage, adoption and operational integration across health systems. - The company will likely continue expanding with academic medical institutions as it pursues scale.